<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11</volume><submitter>Ahmad S</submitter><pubmed_abstract>Derivative synthesis has been a crucial method for altering the effects of already-approved medications, especially to lessen adverse effects and enhance results. Making use of this multi-target approach, a series of naproxen-sulfa drug conjugates was designed and synthesized. The newly designed conjugates were confirmed by spectroscopic techniques like IR, &lt;sup>1&lt;/sup>HNMR, &lt;sup>13&lt;/sup>CNMR, and elemental analysis. The conjugates were screened for anti-inflammatory, urease, and cyclooxygenase-2 (COX-2) inhibition. Naproxen conjugated with sulfanilamide, sulfathiazole, and sulfaguanidine was found potent and showed a competitive mode of urease inhibition, with IC&lt;sub>50&lt;/sub> (µM) values 6.69 ± 0.11, 5.82 ± 0.28, 5.06 ± 0.29, respectively. When compared to other screened conjugates, the n</pubmed_abstract><journal>Frontiers in chemistry</journal><pagination>1206380</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10434765</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Exploring the potential of propanamide-sulfonamide based drug conjugates as dual inhibitors of urease and cyclooxygenase-2: biological and their &lt;i>in silico&lt;/i> studies.</pubmed_title><pmcid>PMC10434765</pmcid><pubmed_authors>Muddassar M</pubmed_authors><pubmed_authors>Ali I</pubmed_authors><pubmed_authors>Yousaf N</pubmed_authors><pubmed_authors>Imran M</pubmed_authors><pubmed_authors>Ahmad S</pubmed_authors><pubmed_authors>Abdul Qadir M</pubmed_authors><pubmed_authors>Zargar S</pubmed_authors><pubmed_authors>Wani TA</pubmed_authors><pubmed_authors>Ahmed M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Exploring the potential of propanamide-sulfonamide based drug conjugates as dual inhibitors of urease and cyclooxygenase-2: biological and their &lt;i>in silico&lt;/i> studies.</name><description>Derivative synthesis has been a crucial method for altering the effects of already-approved medications, especially to lessen adverse effects and enhance results. Making use of this multi-target approach, a series of naproxen-sulfa drug conjugates was designed and synthesized. The newly designed conjugates were confirmed by spectroscopic techniques like IR, &lt;sup>1&lt;/sup>HNMR, &lt;sup>13&lt;/sup>CNMR, and elemental analysis. The conjugates were screened for anti-inflammatory, urease, and cyclooxygenase-2 (COX-2) inhibition. Naproxen conjugated with sulfanilamide, sulfathiazole, and sulfaguanidine was found potent and showed a competitive mode of urease inhibition, with IC&lt;sub>50&lt;/sub> (µM) values 6.69 ± 0.11, 5.82 ± 0.28, 5.06 ± 0.29, respectively. When compared to other screened conjugates, the n</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023</publication><modification>2026-05-28T13:11:36.597Z</modification><creation>2024-10-16T04:56:18.463Z</creation></dates><accession>S-EPMC10434765</accession><cross_references><pubmed>37601915</pubmed><doi>10.3389/fchem.2023.1206380</doi></cross_references></HashMap>